GLPwatch
Papers (12034)
Page 164 of 201, ranked by citation count.
- Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity.
- GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia.
- A review regarding the article 'Semaglutide and heart failure: Updated meta-analysis'.
- [Natriuretic effect of exenatide: high efficacy and site of action].
- A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy.
- Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control.
- Efficacy and Safety of Empagliflozine and Semaglutide (Once Weekly) in T2DM Patients in Shtip.
- [The effects of compound CX09040 on the inhibition of PTP1B and protection of pancreatic β cells].
- GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites.
- Electrospun Nanofiber Oral Thin Film Platform for Sublingual Peptide Delivery: A Promising Alternative to Conventional Semaglutide Formulations.
- Current challenges in type 2 diabetes.
- Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic.
- Association of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis.
- Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes.
- Methyl Proton Spin Relaxation (<i>R</i><sub>2</sub>/<i>R</i><sub>1</sub>) Enables Sensitive Detection of pH-Dependent Oligomerization in GLP-1 Analogs.
- Web Exclusive. Annals On Call - Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes.
- Are glucagon-like peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD)? Does the clinical trial with lixisenatide add anything?
- New Drug Capsule: Tirzepatide.
- Retrospective chart review on psychiatric manifestations of GLP-1 agonist usage.
- Reply to the letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial'.
- Semaglutide in Patients Undergoing Anesthesia for Otolaryngologic Procedures.
- SURMOUNTing body weight barriers in type 2 diabetes.
- Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital.
- Reply: <sup>68</sup>Ga NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.
- Exendin-4 increases the firing activity of hippocampal CA1 neurons through TRPC4/5 channels.
- US eligibility and preventable cardiovascular disease events from semaglutide in type 2 diabetes.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Response to the letter titled reply to "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US".
- Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations.
- How to reset metabolic setpoint in obesity management.
- Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes.
- GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly.
- FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patients.
- Adolescent bariatric surgery-a survey of referring practitioners.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Semaglutide in the treatment of a patient with type 2 diabetes mellitus, psoriasis, and metabolic dysfunction-associated steatotic liver disease: a case report.
- Semaglutide in overweight non-diabetic peritoneal dialysis patients: a real-world single-center experience.
- Approaching therapy of Alzheimer's disease via the antidiabetic drug liraglutide-a study with streptozotocin intracerebroventricularly treated Wistar rats.
- Comparing the performance of electrostatic repulsion-reversed phase chromatography approaches in the resolution of complex peptide mixture: Liraglutide as case study.
- Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis.
- Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.
- Once-Weekly Semaglutide with Lifestyle Intervention Results in Clinically Significant Weight Loss.
- The Potential Weight Loss Benefits Of Tirzepatide: A Double-Edged Sword?
- Assessment of the Potential of GLP-1 Analogs in the Treatment of Addictions: A Literature Review.
- Decreased complexity of glucose dynamics in diabetes in rhesus monkeys.
- Insulin degludec + liraglutide: a complementary combination.
- Semaglutide and Cardiovascular Outcomes.
- Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption.
- Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.
- Recurrent Weight Gain after Weight Loss Induced by Lifestyle Intervention, Metabolic and Bariatric Surgery, or Semaglutide in Adults with Obesity: A Systematic Review of Randomized Controlled Trials.
- Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in indian adults with obesity: A phase III randomized non-inferiority trial.
- Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus.
- Comparative Study of the Effect of Liraglutide and Donepezil on Learning and Memory in Diazepam-Induced Amnesic Albino Rats.
- Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis.
- Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.
- Comparison of the Usability, Accuracy, Preference, and Satisfaction of Three Once-Weekly Glucagon-Like Peptide 1 Receptor Agonist Pen Devices in People With Type 2 Diabetes.
- Liver Fibroblast Growth Factor 21 (FGF21) is Required for the Full Anorectic Effect of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Male Mice fed High Carbohydrate Diets.
- Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity.
- Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trial.
- Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3.